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THE MOLECULAR
BASIS OF CANCER
BY FRANK GORGA
fter cardiovascular diseases, cancer is
the second leading cause of death in
America. Since 1990 over halfa million
Americans have died each year ofsome
form ofcance1; and the number and rate
is still increasing. In 1970 approximately
17 percent of all deaths were attributed
to cancer, while by 1995 the figure had
risen to 24 percent. In her chilling book
on the meaning of illness in America,
Illness as Metaphor, Susan Sontag
described cancer as the sickness of the
Am.erican 20th century. Learning about
cancer has become more than a useful
chore for those who suffer from the
disease or wish to cope with the diseases
offamily members and loved ones. It is
increasingly a matter ofcultural literacy
to com.e to understand the workings ofa
disease whose consequences seem to spare
none of us. In the following essay, Frank
Gorga, Assistant Professor of Chemistry,
summarizes some of the most recent
scientific thinking on the basic nature
ofcancer.

INTRODUCTION

Approximately three decades of intensive research have led to an explosion
in our knowledge of the molecular
and cellular basis of cancer. Perhaps
the most fundamental result of this
research effort is the realization that
cancer is a "genetic" disease. I use the
term "genetic" in a broad fashion.
"Genetic disease" is generally taken
to mean an inherited or inheritable
condition. In a broader sense a genetic
disease results from changes to an
organism's genetic material (i.e. its
DNA). The expression of oncogenes
(literally "cancer genes") within cells
is a crucial event in the ea rl y stages of
tumor formation. Oncogenes can arise
in cells via two mechanisms: infection
of cells by tumor viruses and conversion (mutation) of cellular protooncogenes to oncogenes. These discoveries
and their implications for the prevention, detection and treatment of cancer
are discussed below.
BASIC TUMOR BIOLOGY

Tumors are masses of cells that have
escaped the normal m echanisms that
strictly regulate and limit the growth of
most cells in an animal. The formation
of a clinically recognizable tumor is a
multi -step process. Tumors are thought
to originate via the oncogenic transformation of a single cell. Once a cell is

BRIDGEWATER

REVIEW

transformed it has gained the ability to
grow uncontrollably and microscopic
patches of transformed cells (cancer in
situ, to the pathologists) form. In order
to progress to a clinically significant
(macroscopic) tumor the transformed
cells must be able to avoid the immune
system. In some cases, the ability to
cause angiogenesis (i.e. to stimulate the
growth of blood vessels) is also important in progression to a clinically significant tumor. Relatively late in their
existence, some tumors gain the ability
to escape from the site of their initial
derivation and invade other areas of the
body. This is the process of metastasis.
Each of these processes, oncogenic
transformation, ability to escape recognition by the immune system, angiogenesis and development of metastatic
potential, are associate with genetic
changes. Herein, we will concentrate on
the genetic changes associated with
oncogenic transformation.
THE GENETIC BASIS OF TUMORS

The earliest evidence for the genetic
basis of tumors is probably the discovery in 1911 by Peyton Rous that sarcomas (solid tumors) in chickens could
be transmitted between animals using
a "cell-free filtrate ." The active agent in
this "cell-free filtrate" was found to be a
virus called, aptly, Rous sarcoma virus.
If one takes the view that a virus is a
small "package of genes" with the ability to infect an appropriate host cell and
thereby add the viral genes to the host
cell, then one arrives at the simple
conclusion that tumors can be caused
by the addition (a nd, presumably,
subsequent expression) of genetic
material (i.e. viral DNA) to cells.
In th e years since Rous' work numerous other tumor viruses, infecting various animals, have been discovered.
The significance of"tumor viruses" to
human disease went unappreciated
and, in fact, was hotly debated for a
number of years. The moral and ethical
difficulty in performing the experiment
of infecting a human with a tumorcausing agent makes it impossible to
directly "prove" that a specific virus
causes tumors in humans. However,
molecular epidemiological studies tliat
demonstrate the presence of a specific
viral DNA in the same tumor type from
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THE CENTRAL DOGMA OF BIOLOGY

Genetic information is stored as the sequence of bases in deoxyribonucleic acid
(DNA) within the nucleus of each cell. The expression of genetic information
begins with the synthesis of a messenger RNA molecule (mRNA) whose sequences
of bases is coincide with that of the gene. Proteins are synthesized by "reading"
the bases three at a time and "translating" the mRNA molecule into the amino
acid sequence of the encoded protein. The e,,,_'Pression of genes is under very tight
temporal and spatial control. Changes in the expression of genes result in changes
in the functioning of cells, and ultimately in physiologic changes. Alteration of
the bases within a gene (mutations) result in changes to the encoded protein and,
ultimately, in changes in function.

many individuals provide circumstantial evidence that some human tumors
are the result of viral infection. This
type of correlation has, perhaps, been
most clearly shown in the in the case of
human papilloma virus and cervical
carcinoma as well as Epstein Barr virus
and Burketts lymphoma.
There are a large number of human
and animal tumors that are not associated with viral infection. The evidence
that these tumors also have a genetic
basis comes from three lines of inquiry.
First, was the realization by Bruce Ames
and others that many (most) carcinogens are also mutagens. That is, agents
(including chemicals and radiation)
that are known to cause cancer are also
able to cause damage to DNA. The fact
that damage to DNA can cause cancer
led investigators to (cautiously)
propose that the mutation of normal
cellular genes might play a role in
causing tumors. Further evidence
supporting this hypothesis comes from
applying the tools of molecular genetics
to tumor biology.
Secondly, during the 1970's and '80's,
virologists studying Rous sarcoma
virus were able to show that a single
viral gene among the roughly half
dozen total was responsible for tumorigenesis by these viruses. This oncogene
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(i.e. "cancer causing gene") was named
src (short for "sarcoma") . In 1981,
Michael Bishop and Harold Varmus
made the surprising discovery that normal (i.e. non -tumor) cells contained a
gene that was related to the viral src
gene. This normal cellular gene, called
cellular src (c-src), is a member of a
family of genes called protooncogenes.
Lastly, in 1978, Robert Weinberg and
coworkers demonstrated that there
were oncogenes present in tumors of
non-viral origin. This question was
answered by a simple, elegant gene
transfer e,,,_'Periment in which DNA isolated from tumor cells was used to convert oncogenically transformed normal
cells in culture (see side bar "Gene
Transfer"). This experiment clearly
demonstrated the presence of oncogenes in the large majority of tumors.
Thus, our current understanding
is that tumor formation is initiated by
the expression of an oncogene within
a cell. This expression can be brought
about in two ways. Infection with a
tumor virus and subsequent expression
of viral genes, including the viral
oncogene, is the cause of relatively few
tumors. Most tumors are caused by
the conversion (via mutation) of a
subset of normal cellular genes, the
protooncogenes, into oncogenes.
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The discovery of protooncogenes in
normal cells raises questions regarding
their role in normal cellular processes.
Are protooncogenes silently sitting
within normal cells "waiting" to cause
cancer, or do these genes play a role in
normal physiological processes< The
fact that the protein products of protooncogenes are expressed in (at least
some) normal cells argues strongly for
the latter. Research into the detailed
functioning of many individual protooncogenes has invariably described a
role for the gene and its product in
some physiological process. The
processes in which protooncogenes are
involved is quite varied; however, most
protooncogenes have been found to be
involved (not surprisingly) in the
mechanisms that govern the growth
and differentiation of cells. The biochemical function of protooncogene
products is even more varied. Protooncogenes encoding protein products
that serve as circulating growth factors
and as cell surface receptors for these
growth factors have been discovered.
Many protooncogene products have
been found to serve as components of
the intracellular signal transduction
pathways that serve to transmit the
"signal" generated by growth factors
from the cell surface to the nucleus in
order to effect the changes in gene
expression needed for cellular division.
lMPLLCATLONS FOR THE
0LAGNOSLS AND PREVENTION
OF CANCER

The discovery of protooncogenes and
their mutation to oncogenic forms has
caused a profound change in the way
we think about cancer prevention and
diagnosis. The fact that the ultimate
cause of cancer is genetic change
(mutation) suggests that prevention
of cancer is "simply" a matter of eliminating our exposure to mutagens
(agents that cause mutation) . However,
it is impossible to exist without some
exposure to mutagens. Mutagens,
including cosmic and other radiation,
as well as some mutagenic chemicals,
are present in the natural environment.
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DEMONSTRATION Of
ONCOGENES BY GENE TRANSFER

DNA, isolated from tumor cells (growing in culture) , is mixed with calcium
phosphate and added to normal mouse
cells under conditions where the DNA
can enter the cells (this process is called
transfection). If an oncogene is present
in the DNA, a small number of the
normal cells will become oncogenically
transformed (i.e. "tumor-like") . If
these transformed cells are isolated
and injected into a mouse, they grow
to form a tumor.
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Eliminating exposure to these agents
is physically impossible. Thus, oncogenic mutation and cancer must be
considered to be a (partially) natural
phenomenon. The "best" we can hope
for is to minimize, taking into account
the economic and social costs, our
exposure to mutagens that result from
human activity and thus minimize the
frequency of oncogenic mutations.
The discovery of oncogenic mutations also helps to explain the observation that incidence of cancer, in
general, rises with age. Simply, given a
constant (or nearly constant) rate of
mutation , the longer people live the
greater the chance that they will suffer
an oncogenic mutation somewhere in
their bodies.
The existence of oncogenic mutations opens new possibilities in the
detection of cancer. Currently, most
cancers are detected indirectly by the
symptoms they cause. Thus, tumors
must be large enough to "cause
problems" before they are detected .
However, the earlier a tumor is
detected, the smaller it is, and the less
likely it will have spread to other tissues
(metastasize); thus the more "curable"
the tumor is. If one can design specific
molecular-level probes for oncogenes
or their products, it should be possible
to devise a diagnostic test that may
allow earlier and more accurate
detection of tumors. One (somewhat
controversial) example of this idea is
the test for prostate-specific antigen
(PSA) used in the screening of men for
prostate tumors.
lMPLICATIONS FOR
ANTI-TUMOR THERAPY

The discovery of protooncogenes and
their varied functions has also dramatically changed our view of anti-tumor
therapy. Most current anti-tumor therapies (including chemotherapeutic
drugs and radiation treatments) are not
"anti-tumor" per se. These treatments
target rapidly growing cells and thus
affect a number of normal tissues in
addition to tumors, thereby causing the
side effects associated with anti-tumor
therapy (see side bar "Anti -tumor
Therapy"). Discovery of oncogenes
and the gaining of detailed information
about the biochemical activity of their
products is both discouraging and
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encouraging in terms of anti-tumor
therapy. The (relatively) large number
of oncogenes underscores the fact that
"cancer" is not a single disease and
means that there will be no "magic
bullet" that will cure all (or even most)
tumors. On the other hand, each
known oncogene, and its product,
represents a known potential target for
anti-tumor therapy. Development of
drugs that specifically interfere with
the activity of a particular oncogene
product should allow more effective
treatment of the tumors caused by
expression of that particular oncogene,
including a large decrease in the side
effects of the anti-tumor therapy. In
addition, "anti-sense" therapy designed
to specifically disrupt the expression
of oncogenes represents a powerful
new, although unproven, approach to
anti-tumor therapy.

SIDE EFFECTS OF
ANTI-TUMOR THERAPY

Anti-tumor radiation treatment
and most current chemotherapy
drugs work by interfering with
DNA replication or some other
aspect of cellular division. Thus
these agents do not specifically
target tumor cells; rather they kill
both tumor cells and normal
cells that happen to grow rapidly.
One consequence of tl1is lack of
specificity is the side effects of
cancer treatment. Although most
cells in the adult body do not
grow, or do so slowly, there are
tissues whose function requires
the regular replenishment of
cells. These tissues contain populations of cells that grow rapidly
during the course of normal
functioning. Many of the side
effects of anti-tumor therapy,
including loss of hair, nausea and
immunosupression, are directly
attributable to disruption of
rapidly growing cell populations
in hair follicles, the intestines,
and bone marrow, respectively.
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A~m-SENSE TECHNOLOGY

Much of nucleic acid structure and function is based on base-pairing interactions
between the building blocks (bases) of DNA and RNA. These complementary
interactions are specific in that within a DNA molecule adeni ne (A) always pairs
with thymidine (T) and guanine (G) always pairs with cytidine (C). In RNA, thymidine is replaced with uracil (U), which also pairs with adenine, but the "rules" of
bases pairing are otherwise the same. Anti-sense technology is a method for disrupting the expression of a specific protein with in cells. This technology involves
the introduction (into a cell) of an anti-sense DNA that is complementary to the
mRNA that encodes the protein of interest. This anti-sense DNA binds specifically
to the mRNA (via specific base pairing) and inhibits its translation into protein.
Thus, this technology allows the specific disruption of the production of a single
protein within cells. Although anti-sense technology is currently useful in the lab,
the technology for delivery of anti-sense DNA's in whole organisms is still under
development. Once the technology is fully developed, disruption of oncogene
expression using this technique should be an effective anti-tumor therapy.

CONCLUSION

That three decades of intensive research
in oncology and related basic sciences
has not led to a cure for cancer may
seem disappointing to the general
public; it has, however, led scientists
to a much better understanding of the
"problem" of cancer. The discovery
of the genetic basis for tumorigenesis,
along with the advent of"biotechnology" holds great promise that the
next thirty years will bring both more
effective anti-tumor therapies and
greatly improved diagnosis
of tumors.
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SOURCES OF FURTH Ell
INFORMATION

• CancerNet
(http: //ca ncernet.nci.nih.gov/)
This web site (maintained by the
National Ca ncer Institute) has information on cancer at all levels. Material
appropriate for patients (a nd other
non-specialists) is maintained, as well
as specialized information for health
professionals and basic researchers.
• Scientific American ,
September 1996
(http: //www.sciam .com/0996issue/
0996currentissue.html)
This special issue of Scientific
American titled "What You Need To
Know About Cancer" has numerous
articles dealing, in more detail, with
many of the issues covered herein.
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· Nobel Prizes
Two Nobel Prizes have been awarded
for work related to tumor viruses and
oncogenes. The 1975 Nobel Prize in
Physiology or Medicine was awarded
jointly to David Baltimore, Renato
D ulbecco and Howard Temin "for their
discoveries concerning the interactio n
between tumour viruses and the
genetic material of the cell'.' More
information can be found at the Nobel
Foundation's web site (http://www.
nobel.se/laureates/medicine-1975.
html ). In 1989, the Nobel Prize for
Physiology or Medicine was awa rded
jointly to J. Michael Bishop and Harold
Va rmus, "for their discovery of the
cellular origin of retroviral oncogenes"
(http://www.nobel.se/laureates/
medicine-1989.html). Bishop's (Biosci
Rep. 10(6): 473-491, 1990) and Varmus'
(Biosci Rep. 10(5) : 413-430, 1990)
acceptance speeches were published
in Bioscience Reports.

Frank Gorga is Assistant Professor of
Chemical Sciences
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